Stereotactic MRI-Guided Radiation for Localized Prostate Cancer

Not Applicable

• Conditions: Prostate Cancer
• Interventions: Radiation: SABR

• Registration Number: NCT03588819
• Lead Sponsor: Sunnybrook Health Sciences Centre

Brief Summary

This single arm, prospective study will determine the prostate-specific quality of life (QOL) of patients undergoing undergoing a 2 fraction MRI-guided stereotactic ablative body radiation (SABR) protocol. We propose prescribing a prostate dose of 26 Gy in 2 fractions and a dose of up to 32 Gy to the dominant intraprostatic lesion (DIL) in 2 fractions over one week.

Detailed Description

Stereotactic Ablative Body Radiation Two weekly fractions of:

13 Gy to whole prostate +/- seminal vesicles AND Up to 16 Gy simultaneous boost to dominant MRI nodule

Treatment Delivery and Quality Assurance Treatment will be delivered on treatment units equipped with with volumetric arc therapy and hexapod couches. Only photons with megavoltage energies of 6 MV will be used. Cone-beam CT imaging will be performed using the implanted fiducials to set up each treatment. Imaging after each fraction of radiation will be performed and the shifts in prostate positioning (as measured by displacement of gold seed fiducials) will be measured and recorded. Also, the total treatment time for each fraction of radiotherapy will be recorded.

Patient Assessments / Follow-up Time zero will be the start of radiotherapy. Baseline and follow-up parameters are as listed in Appendix A. Baseline rectal and urinary function will be recorded. Acute toxicities will be assessed at weeks 1, 4, and 13 and late toxicities will be assessed at month 6 and every 6 months until year 5 using the Common Terminology Criteria Adverse Events, version 4.0. Bloodwork (PSA and testosterone), will be performed at months 3, 6 and every 6 months until year 5. QOL using the Expanded Prostate Cancer Index Composite (EPIC) will be obtained at baseline, weeks 1, 4, 13, month 6 and every 6 months until year 5.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-04-23
• Study First Submitted: 2018-07-02
• Study First Submitted QC: 2018-07-16
• Study First Posted: 2018-07-17
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-12
• Last Update Posted: 2022-06-14
• Primary Completion: 2024-01-23
• Study Completion: 2024-04-23

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

1. Informed consent obtained
2. Men >18 years
3. Histologically confirmed prostate adenocarcinoma (centrally reviewed)
4. Favorable risk prostate cancer, defined as clinical stage T1-2c, Gleason Sum less than or equal to 7, and PSA less than or equal to 20 ng/mL (patients can have only one of T2c, Gleason Sum 7 and PSA 10-20 ng/ml)

Read More

Exclusion Criteria

1. Androgen deprivation therapy (LHRH-agonists or antiandrogens) > 6 mo
2. Prior pelvic radiotherapy
3. Anticoagulation medication (if unsafe to discontinue for gold seed insertion)
4. Diagnosis of bleeding diathesis
5. Large prostate (>90cm3) on imaging
6. Immunosuppressive medications
7. Inflammatory bowel disease
8. Presence of a hip prosthesis
9. Contraindications to having MRI

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
2-fraction SABR	SABR	-

Primary Outcome Measures

Name	Time	Method
QOL	5 years	To determine the prostate-specific quality of life (QOL) using the Expanded Prostate Cancer Index Composite (EPIC)

Secondary Outcome Measures

Name	Time	Method
PSA	5 years	Proportion of patients with 4 year PSA value \< 0.4 ng/ml
Late Toxicity	5 Years	Incidence of late (≥6 months) complications of interest (CTCAE v4)
Salvage Therapy	5 years	Rate of salvage therapy (ADT, surgery or brachytherapy)
Acute Toxicity	3months	Incidence of acute (≤3 months) complications of interest using Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE v4)
Health Utilities	5 year	Health utilities using the Patient Oriented Prostate Ultility Scale (PORPUS-U) (0=best quality of life to 1=worst quality of life)
Biochemical Recurrance	5 years	5 year biochemical failure rates using the Phoenix definition (nadir PSA + 2 ng/mL)

Trial Locations

Locations (1)

Sunnybrook Health Sciences Centre; 🇨🇦 Toronto, Ontario, Canada